학술논문
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
Document Type
article
Author
James Brett Case; Samantha Mackin; John M. Errico; Zhenlu Chong; Emily A. Madden; Bradley Whitener; Barbara Guarino; Michael A. Schmid; Kim Rosenthal; Kuishu Ren; Ha V. Dang; Gyorgy Snell; Ana Jung; Lindsay Droit; Scott A. Handley; Peter J. Halfmann; Yoshihiro Kawaoka; James E. Crowe; Daved H. Fremont; Herbert W. Virgin; Yueh-Ming Loo; Mark T. Esser; Lisa A. Purcell; Davide Corti; Michael S. Diamond
Source
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
SARS-CoV-2 variants of concern are less susceptible to therapeutic neutralizing antibodies, given mutations in the surface glycoprotein S. Here, Case et al. show that therapeutic antibodies S309 and AZD7442 reduce lung infection with SARSCoV-2 Omicron lineages in humanized mouse model despite the loss of neutralizing potency in vitro.